Article
Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation.
European journal of clinical pharmacology - 1 Dec 2007
Fromm Martin F, Schwilden Helmut, Bachmakov Iouri, König Jörg, Bremer Frank, Schüttler Jürgen
Abstract excerpt
OBJECTIVE: Information is lacking on whether the CYP3A5 genotype affects the disposition and effects of midazolam during the long-term intensive care sedation of patients. This study was undertaken to estimate whether the CYP3A5 genotype can explain a relevant portion of pharmacokinetic interindividual variability. METHODS: We determined the CYP3A5 genotype in 71 Caucasian patients who underwent long-term...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
